Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Lucio N Gordan"'
Autor:
Lucio N. Gordan, David Ray, Stephen C. Ijioma, George Dranitsaris, Amanda Warner, Trevor Heritage, Matthew Fink, David Wenk, Paul Chadwick, Natasha Khrystolubova, Shachar Peles
Publikováno v:
Current Oncology, Vol 31, Iss 1, Pp 501-510 (2024)
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use of supportive care and patient education. We investigated the impact of a BP program in patients
Externí odkaz:
https://doaj.org/article/03fbdb730e0f4021a45793e1fd5c3ec3
Publikováno v:
Immunotherapy Weekly; 12/5/2023, p497-497, 1p
Autor:
Scott S Tykodi, Daniel J George, Jeff Yorio, Lucio N Gordan, Joshua Zhang, Jennifer L Johansen, Arash Rezazadeh Kalebasty, David R Spigel, Samith T Kochuparambil, Ana M Molina, Heidi McKean, Nishan Tchekmedyian, Margarita Askelson, Thomas E Hutson
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Objectives The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this mod
Externí odkaz:
https://doaj.org/article/a35e5923581b4b07b7b03b97b3b2d842
Autor:
Thomas Hutson, Peter Van Veldhuizen, Michael R Harrison, Scott S Tykodi, Daniel J George, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Ivor Percent, Rakesh Singal, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Background CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features
Externí odkaz:
https://doaj.org/article/2afaa38ab63544b783e82c3073c180bf
Autor:
Bradley Curtis Carthon, Jesus Zoco, Thomas E. Hutson, Mark R. Olsen, Edward Arrowsmith, Johanna C. Bendell, Hamid Emamekhoo, Joshua Zhang, Daniel J. George, Scott S. Tykodi, David Leung, Ana M. Molina, Alexandra Drakaki, Lucio N. Gordan, Ivor John Percent, Daniel C. Cho, Jennifer L. Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Cancer. 128:966-974
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47447a8d84cc5d3bc187e0281ee97bfe
https://doi.org/10.1002/cncr.34016
https://doi.org/10.1002/cncr.34016
Publikováno v:
Future oncology (London, England). 18(3)
Background: The introduction of daratumumab into the treatment of multiple myeloma has improved outcomes in patients; however, community oncologists often dose more frequently than the US FDA-approved label. Materials and methods: Integra analyzed it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d63f42185274be9eec075d9f50df4739
https://pubmed.ncbi.nlm.nih.gov/34709061
https://pubmed.ncbi.nlm.nih.gov/34709061
Autor:
Daniel J George, David R Spigel, Lucio N Gordan, Samith T Kochuparambil, Ana M Molina, Jeff Yorio, Arash Rezazadeh Kalebasty, Heidi McKean, Nishan Tchekmedyian, Scott S Tykodi, Joshua Zhang, Margarita Askelson, Jennifer L Johansen, Thomas E Hutson
Publikováno v:
BMJ Open. 12:e058396
ObjectivesThe non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this modi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d61f69c2a60ef790779f03ad7748425d
https://doi.org/10.1136/bmjopen-2021-058396
https://doi.org/10.1136/bmjopen-2021-058396